Research programme: cachexia and anorexia therapeutics - Obexia
Alternative Names: 1E8a scFv; OBX 1201; OBX 1202Latest Information Update: 28 Apr 2018
At a glance
- Originator Obexia
- Class Monoclonal antibodies
- Mechanism of Action Melanocortin type 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Anorexia; Cachexia
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Anorexia in Switzerland (IV)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Cachexia in Switzerland (IV)
- 26 Sep 2016 Research programme: cachexia and anorexia therapeutics - Obexia is available for licensing as of 26 Sep 2016. http://obexia.com/about.php